Thermo Fisher Scientific Inc. $TMO Shares Bought by TD Private Client Wealth LLC

TD Private Client Wealth LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 89.7% in the 4th quarter, Holdings Channel reports. The fund owned 9,530 shares of the medical research company’s stock after purchasing an additional 4,505 shares during the period. TD Private Client Wealth LLC’s holdings in Thermo Fisher Scientific were worth $5,522,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Howard Capital Management Inc. grew its position in Thermo Fisher Scientific by 0.5% in the fourth quarter. Howard Capital Management Inc. now owns 3,091 shares of the medical research company’s stock valued at $1,791,000 after acquiring an additional 16 shares in the last quarter. Petros Family Wealth LLC grew its position in Thermo Fisher Scientific by 3.9% in the fourth quarter. Petros Family Wealth LLC now owns 456 shares of the medical research company’s stock valued at $264,000 after acquiring an additional 17 shares in the last quarter. Salomon & Ludwin LLC lifted its stake in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company’s stock worth $669,000 after acquiring an additional 17 shares in the last quarter. Pallas Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 1.5% in the fourth quarter. Pallas Capital Advisors LLC now owns 1,256 shares of the medical research company’s stock worth $728,000 after acquiring an additional 18 shares in the last quarter. Finally, Red Door Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 0.8% in the fourth quarter. Red Door Wealth Management LLC now owns 2,156 shares of the medical research company’s stock worth $1,250,000 after acquiring an additional 18 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $442.16 on Tuesday. The stock has a fifty day moving average price of $484.46 and a two-hundred day moving average price of $541.15. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $164.31 billion, a P/E ratio of 24.31, a PEG ratio of 1.94 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter in the prior year, the firm earned $5.15 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Jefferies updated its “Franchise Picks” list of highest-conviction buy-rated stocks, and Thermo Fisher Scientific was included among names viewed favorably by the broker. Jefferies updates its list of highest-conviction Buy-rated stocks
• Positive Sentiment: Thermo Fisher announced a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, expanding its PPD Clinical Research business and strengthening its global drug-development support capabilities. Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
• Positive Sentiment: A market outlook report highlighted the life science instrumentation market as a growth area through 2031, naming Thermo Fisher as a leading player alongside peers like Danaher and Agilent. Life Science Instrumentation Market Forecast Report 2025-2031
• Positive Sentiment: Wall Street analysts continue to view Thermo Fisher Scientific favorably, with coverage pointing to a “Moderate Buy” consensus and a constructive longer-term outlook. Thermo Fisher Scientific Inc. Receives Average Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Several articles focused on TMO’s recent share-price weakness and valuation debate, reflecting investor caution rather than a clear new fundamental catalyst. Thermo Fisher Scientific (TMO) Valuation Check After Recent Share Price Weakness
• Neutral Sentiment: Thermo Fisher also drew attention for opening a Bioprocess Design Center in Plainville, Massachusetts, which supports long-term innovation but is not likely to move the stock immediately. Thermo Fisher Scientific Inc. Unveils Bioprocess Design Center to Develop Life-Changing Therapies
• Negative Sentiment: A broader market selloff tied to hotter-than-expected PPI inflation pressured Thermo Fisher along with other healthcare and pharma names, adding to recent stock weakness. Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know

Analysts Set New Price Targets

Several research analysts recently commented on the company. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Citigroup boosted their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Morgan Stanley reiterated an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $616.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.